Point-of-Care Value Cholestech specializes in rapid, point-of-care diagnostic systems that deliver results in about 5 minutes, presenting a compelling opportunity to upsell integrated testing workflows, consumables, and service contracts to clinics and independent labs seeking faster patient throughput.

Mid-Market Focus With 51-200 employees and revenue in the 10-25 million range, Cholestech sits in a mid-market niche that often seeks scalable, cost-effective lab solutions; target mid-size clinics, urgent care centers, and regional labs looking to modernize lipid, glucose, and inflammatory testing.

Product Ecosystem The LDX and GDX systems cover cholesterol, lipids, glucose control, inflammation, and liver enzymes; opportunities exist to cross-sell reagents, calibration materials, and software analytics to optimize point-of-care workflows and data management.

Financial Growth Potential With disclosed revenue and a dedicated funding round, there is room to propose bundled financing, extended warranty, and training packages to accelerate adoption in hospitals or multi-site clinics, aligning with a buyer’s need for predictable TCO.

Competitive Differentiation Compared to larger diagnostics players, Cholestech’s agility and affordability can be leveraged to position as a complementary partner for regional networks or private-label OEM opportunities, offering flexible partnerships, service levels, and rapid deployment timelines.